
Opinion|Videos|May 12, 2025
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
Panelists discuss how evaluating a renal mass requires considering multiple factors, including patient expectations, comorbidities, life expectancy, tumor characteristics such as size and enhancement patterns, and predictive models to help guide decision-making.
Advertisement
Episodes in this series

Clinical Challenges in Renal Mass Evaluation
Main Discussion Topics:
- Multiple factors influence management decisions, including patient expectations, comorbidities, life expectancy, and tumor characteristics.
- Tumor assessment includes size, growth kinetics, and enhancement characteristics.
- Predictive models help assess patient longevity and tumor behavior.
Key Points for Physicians:
- Comprehensive assessment requires consideration of patient factors and tumor characteristics.
- Enhancement patterns on imaging provide valuable diagnostic information.
- Existing predictive models can help guide clinical decision-making.
Notable Insights:
Decision-making for renal masses requires a multifaceted approach that integrates patient-specific factors with tumor radiographic characteristics.
Clinical Significance:
A systematic approach that considers both patient factors and tumor characteristics leads to more appropriate management decisions for renal masses.
Advertisement
Related to this article

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5

